Actualités Nurexone Biologic Inc - NRX | Actions TSX Venture Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Secures Master Cell Bank

TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

Company demonstrates reliable production from multiple biological sourcesThese manufacturing advancements...

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

TORONTO and HAIFA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Nurexone Biologic Inc (NRX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

NRX Actualités

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Biologic Secures Master Cell Bank

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Nurexone Biologic Inc (NRX) Actualités

Nurexone Biologic Inc (NRX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

NRX Actualités

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Biologic Secures Master Cell Bank

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités